MARKET

ICCM

ICCM

Icecure Medical Ltd.
NASDAQ
1.230
-0.060
-4.65%
After Hours: 1.270 +0.04 +3.25% 18:53 04/18 EDT
OPEN
1.280
PREV CLOSE
1.290
HIGH
1.280
LOW
1.230
VOLUME
105.94K
TURNOVER
0
52 WEEK HIGH
1.570
52 WEEK LOW
0.5200
MARKET CAP
56.25M
P/E (TTM)
-3.8318
1D
5D
1M
3M
1Y
5Y
BTTR, ICCM and SXTC among pre-market losers
Seeking Alpha · 1d ago
HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)
TipRanks · 2d ago
IceCure Medical Announces Upcoming Shareholders Meeting
TipRanks · 3d ago
IceCure Medical Eyes FDA Approval with Promising Trial Results
TipRanks · 3d ago
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results; Data Submitted To FDA Requesting Marketing Authorization To Treat Early-Stage Breast Cancer
Data presentation at highly influential American Society of Breast Surgeons Annual Meeting by Dr. Richard Fine wins Scientific Impact Award. Company seeks indication for treating women with early stage T1 invasive breast cancer with adjuvant hormone therapy. ProSense® cryoablation offers highly favorable healthcare economics.
Benzinga · 3d ago
ICECURE MEDICAL REPORTS FINAL ICE3 BREAST CANCER CRYOABLATION TRIAL RESULTS OF 100% PATIENT AND PHYSICIAN SATISFACTION AND 96.3% RECURRENCE FREE RATE: DATA SUBMITTED TO FDA REQUESTING MARKETING AUTHORIZATION TO TREAT EARLY-STAGE BREAST CANCER
Reuters · 3d ago
Weekly Report: what happened at ICCM last week (0408-0412)?
Weekly Report · 3d ago
More
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

Webull offers Icecure Medical Ltd stock information, including NASDAQ: ICCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICCM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ICCM stock methods without spending real money on the virtual paper trading platform.